our Premium Content: News alerts, weekly reports and conference planners

GENE:

CHD2 (Chromodomain Helicase DNA Binding Protein 2)

News alerts, weekly reports and conference planners

In vivo multiplexed modeling reveals diverse roles of the TBX2 subfamily and Egr1 in Kr as-driven lung adenocarcinoma. (PubMed, Genes Dis)

Transcriptomic analyses of Egr1-deficient tumors suggested immune dysregulation, including heightened inflammation and potential markers of T cell exhaustion in the tumor microenvironment. These findings indicate that Egr1 may play a role in suppressing tumor growth through modulating immune dynamics, offering new insights into the interplay between tumor progression and immune regulation in lung adenocarcinoma.

5 days ago

Preclinical • Journal

RB1 (RB Transcriptional Corepressor 1) • TNFAIP3 (TNF Alpha Induced Protein 3) • ATF3 (Activating Transcription Factor 3) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • EGR1 (Early Growth Response 1)

2ms

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL (clinicaltrials.gov)

P2, N=22, Recruiting, Zulfa Omer | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SF3B1 (Splicing Factor 3b Subunit 1) • CD79B (CD79b Molecule) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • BIRC3 (Baculoviral IAP repeat containing 3) • CD5 (CD5 Molecule) • POT1 (Protection of telomeres 1) • H1-4 (H1.4 Linker Histone, Cluster Member) • NFKBIE (NFKB Inhibitor Epsilon) • ZMYM3 (Zinc Finger MYM-Type Containing 3) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • FCER2 (Fc Fragment Of IgE Receptor II)

Chr del(11q)

clonoSEQ

Gazyva (obinutuzumab) • Epkinly (epcoritamab-bysp)

2ms

ESR-23-22182: Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL (clinicaltrials.gov)

P2, N=62, Recruiting, Zulfa Omer | Not yet recruiting --> Recruiting | Initiation date: Jun 2025 --> Dec 2025

2 months ago

Enrollment open • Trial initiation date

Chr del(11q)

clonoSEQ

Venclexta (venetoclax) • Calquence (acalabrutinib)

4ms

DNA methylation profiles and cancer in children conceived after assisted reproductive technology. (PubMed, Clin Epigenetics)

This study indicates that relatively few genes that are known targets for somatic/germline mutation in cancer experience DNA methylation changes in individuals conceived through ART. By contrast, DNA methylation disturbances reported in leukemia represent more than one-third of those associated with ART conception, thus raising the question of their role in leukemia risk in ART-conceived individuals. Among them, a few critical genes such as TP73, a tumor suppressor, were shown to be targeted for hypermethylation, both in ART and leukemia, warranting further investigation.

4 months ago

Journal

FGFR2 (Fibroblast growth factor receptor 2) • TP73 (Tumor Protein P73) • CHD2 (Chromodomain Helicase DNA Binding Protein 2)

11ms

In Vivo Multiplexed Modeling Reveals Diverse Roles of the TBX2 Subfamily and Egr1 in Ras -Driven Lung Adenocarcinoma. (PubMed, bioRxiv)

Transcriptomic analyses of Egr1 -deficient tumors suggested immune dysregulation, including heightened inflammation and potential markers of T cell exhaustion in the tumor microenvironment. These findings indicate that Egr1 may play a role in suppressing tumor growth through modulating immune dynamics, offering new insights into the interplay between tumor progression and immune regulation in LUAD.

11 months ago

Preclinical • Journal

1year

Pilot study: Initial investigation suggests differences in EMT-associated gene expression in breast tumor regions. (PubMed, Comput Struct Biotechnol J)

All significant genes were analyzed for pathway enrichment using MSigDB and Gene Ontology databases, most notably the epithelial to mesenchymal transition and cell motility pathways. This pilot study highlights key genes of interest that are differentially expressed in African American and Caucasian TNBC samples.

1 year ago

Journal

EGF (Epidermal growth factor) • SNAI1 (Snail Family Transcriptional Repressor 1) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • ITGB1 (Integrin Subunit Beta 1)

1year

Molecular Profiling of Sinonasal Adenoid Cystic Carcinoma: Canonical and Noncanonical Gene Fusions and Mutation. (PubMed, Am J Surg Pathol)

Noncanonical fusions were predominantly observed in metatypical AdCCs. These findings emphasize the value of comprehensive molecular profiling in correlating morphologic characteristics, genetic landscape, and clinical behavior in AdCC.

1 year ago

Journal

PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NOTCH1 (Notch 1) • NF1 (Neurofibromin 1) • RUNX1 (RUNX Family Transcription Factor 1) • PALB2 (Partner and localizer of BRCA2) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CREBBP (CREB binding protein) • BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1) • KDM6A (Lysine Demethylase 6A) • EP300 (E1A binding protein p300) • DDX41 (DEAD-Box Helicase 41) • PHF6 (PHD Finger Protein 6) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D) • NFIB (Nuclear Factor I B) • RIT1 (Ras Like Without CAAX 1) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • DNM3 (Dynamin 3) • GEN1 (GEN1 Holliday junction 5' flap endonuclease) • LZTR1 (Leucine Zipper Like Transcription Regulator 1) • MYBL1 (MYB Proto-Oncogene Like 1) • TAF1 (TATA-Box Binding Protein Associated Factor 1)

over1year

Pathogenic variants of mycosis fungoides identified using next-generation sequencing. (PubMed, J Hematop)

NGS may enhance MF diagnosis, as the detection of pathogenic variants, particularly those known to occur in MF, favors a neoplastic diagnosis over an inflammatory diagnosis. Continuing this work may lead to the discovery of therapeutic targets.

over 1 year ago

Journal • Next-generation sequencing • IO biomarker

DNMT3A (DNA methyltransferase 1) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • HLA-B (Major Histocompatibility Complex, Class I, B) • SOCS1 (Suppressor Of Cytokine Signaling 1) • CHD2 (Chromodomain Helicase DNA Binding Protein 2)

DNMT3A mutation

over1year

ALK-positive large B-cell lymphoma: a clinicopathological and molecular characteristics analysis of seven cases. (PubMed, Pathology)

We present seven cases of ALK+ LBCL, discussing the correlation between fusion genes and ALK protein expression, and enhancing our understanding of the genetic attributes of this tumour. This study also shows the loss of 5hmC in nearly all seven ALK+ LBCL cases, independently of TET2 mutations.

over 1 year ago

Journal • IO biomarker

ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • LRP1B (LDL Receptor Related Protein 1B) • CLTC (Clathrin Heavy Chain) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • PABPC1 (Poly(A) Binding Protein Cytoplasmic 1) • SEC31A (SEC31 Homolog A COPII Coat Complex Component)

ALK positive • ALK rearrangement • ALK fusion • TET2 mutation • NPM1-ALK fusion

over1year

IGF1R and FLT1 in female endothelial cells and CHD2 in male microglia play important roles in Alzheimer's disease based on gender difference analysis. (PubMed, Exp Gerontol)

IGF1R and FLT1 in endothelial cells contribute to AD in females, while CHD2 negatively regulates ribosome pathway gene expression in male microglia, suppressing AD in humans and mice.

over 1 year ago

Journal

FLT1 (Fms-related tyrosine kinase 1) • APOE (Apolipoprotein E) • CHD2 (Chromodomain Helicase DNA Binding Protein 2)

over1year

Comprehensive Analysis of the Expression, Prognosis, and Immune Infiltrates for Chromodomain-Helicase-DNA-Binding Proteins in Breast Tumor. (PubMed, Asian Pac J Cancer Prev)

The altered expression of some CHD members was significantly related to clinical cancer outcomes, and CHD1/2/8/9 could serve as potential prognostic biomarkers to improve the survival of BrCa patients. However, to evaluate the studied CHD members in detail are needed further investigations including experimental validation.

over 1 year ago

Journal • BRCA Biomarker • Epigenetic controller

CHD1 (Chromodomain Helicase DNA Binding Protein 1) • CHD8 (Chromodomain Helicase DNA Binding Protein 8) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • MIR615 (MicroRNA 615) • MIRLET7B (MicroRNA Let-7b)

almost2years

CHD2 Regulates Neuron-glioma Interactions in Pediatric Glioma. (PubMed, Cancer Discov)

Mechanistically, CHD2 coordinates with the transcription factor FOSL1 to control the expression of axon-guidance and synaptic genes in H3.1K27M DMG cells. Together, our study reveals a mechanism whereby CHD2 controls the intrinsic gene program of the H3.1K27M DMG subtype, which in turn regulates the tumor growth-promoting interactions of glioma cells with neurons.

almost 2 years ago

Journal

FOSL1 (FOS Like 1) • CHD2 (Chromodomain Helicase DNA Binding Protein 2)